Mortality risk by hemodialyzer reuse practice and dialyzer membrane characteristics: Results from the USRDS dialysis morbidity and mortality study

被引:115
作者
Port, FK
Wolfe, RA
Hulbert-Shearon, TE
Daugirdas, JT
Agodoa, LYC
Jones, C
Orzol, SM
Held, PJ
机构
[1] Univ Michigan, KECC, Dept Internal Med, Ann Arbor, MI 48103 USA
[2] US Renal Data Syst Coordinating Ctr, Ann Arbor, MI 48103 USA
[3] Univ Michigan, KECC, Dept Epidemiol, Ann Arbor, MI 48103 USA
[4] Univ Michigan, KECC, Dept Biostat, Ann Arbor, MI 48103 USA
[5] Univ Renal Res & Educ Assoc, Ann Arbor, MI USA
[6] Westside Vet Adm Med Ctr, Chicago, IL USA
[7] NIDDKD, Bethesda, MD 20892 USA
关键词
hemodialysis (HD) mortality; dialysis reuse; dialyzer reprocessing; dialysis membrane; bleach in reuse; high-flux dialysis;
D O I
10.1053/ajkd.2001.21290
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Hemodialyzer reuse is commonly practiced in the United States. Recent studies have raised concerns about the mortality risk associated with certain reuse practices. We evaluated adjusted mortality risk during 1- to 2-year follow-up in a representative sample of 12,791 chronic hemodialysis patients treated in 1,394 dialysis facilities from 1994 through 1995. Medical record abstraction provided data on reuse practice, use of bleach, dialyzer membrane, dialysis dose, and patient characteristics and comorbidity. Mortality risk was analyzed by bootstrapped Cox models by (1) no reuse versus reuse, (2) reuse agent, and (3) dialyzer membrane with and without the use of bleach, while considering dialysis and patient factors. The relative risk (RR) for mortality did not differ for patients in reuse versus no-reuse units (RR = 0.96; 95% confidence interval [CI], 0.86 to 1.08; P > 0.50), and similar results were found with different levels of adjustment and subgroups (RR = 1.01 to 1.05; 95% CI, lower bound > 0.90, upper bound < 1.19 each; each P > 0.40). The RR for peracetic acid mixture versus formalin varied significantly by membrane type and use of bleach during reprocessing, achieving borderline significance for synthetic membranes. Among synthetic membranes, mortality was greater with low-flux than high-flux membranes (RR = 1.24; 95% CI, 1.02 to 1.52; P = 0.04) and without than with bleach during reprocessing (RR = 1.24; 95% CI, 1.01 to 1.48; P = 0.04), Among all membranes, mortality was lowest for patients treated with high-flux synthetic membranes (RR = 0.82; 95% CI, 0.72 to 0.93; P = 0.002). Although mortality was not greater in reuse than no-reuse units overall, differences may exist in mortality risk by reuse agent. Use of high-flux synthetic membrane dialyzers was associated with lower mortality risk, particularly when exposed to bleach. Clearance of larger molecules may have a role. (C) 2001 by the National Kidney Foundation, Inc.
引用
收藏
页码:276 / 286
页数:11
相关论文
共 43 条
[1]  
[Anonymous], USRDS 1999 ANN DAT R
[2]  
[Anonymous], USRDS 1998 ANN DAT R
[3]  
BARIS E, 1993, CAN MED ASSOC J, V148, P175
[4]   The safety of reusing ablation catheters with temperature control and the need for a validation protocol and guidelines for reprocessing [J].
Blomström-Lundqvist, C .
PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1998, 21 (12) :2563-2570
[5]   INFECTIONS WITH MYCOBACTERIUM-CHELONEI IN PATIENTS RECEIVING DIALYSIS AND USING PROCESSED HEMODIALYZERS [J].
BOLAN, G ;
REINGOLD, AL ;
CARSON, LA ;
SILCOX, VA ;
WOODLEY, CL ;
HAYES, PS ;
HIGHTOWER, AW ;
MCFARLAND, L ;
BROWN, JW ;
PETERSEN, NJ ;
FAVERO, MS ;
GOOD, RC ;
BROOME, CV .
JOURNAL OF INFECTIOUS DISEASES, 1985, 152 (05) :1013-1019
[6]   Initial experience with reuse of coronary angioplasty catheters in the United States [J].
Browne, KF ;
Maldonado, R ;
Telatnik, M ;
Vlietstra, RE ;
Brenner, AS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (07) :1735-1740
[7]  
BURR D, 1989, J AM STAT ASSOC, V20, P1290
[8]   ANAPHYLATOXIN FORMATION DURING HEMODIALYSIS - COMPARISON OF NEW AND RE-USED DIALYZERS [J].
CHENOWETH, DE ;
CHEUNG, AK ;
WARD, DM ;
HENDERSON, LW .
KIDNEY INTERNATIONAL, 1983, 24 (06) :770-774
[9]  
Cheung AK, 1999, J AM SOC NEPHROL, V10, P117
[10]  
Collins AJ, 1998, J AM SOC NEPHROL, V9, P2108